Iridex Corp (IRIX)
NASDAQ:IRIX
IRIX Stock Chart & Stats
$1.23
-$0.02(-1.39%)
At close: 4:00 PM EST
$1.23
-$0.02(-1.39%)
Day’s Range― - ―
52-Week Range$0.87 - $1.65
Previous CloseN/A
Volume8.51K
Average Volume (3M)66.91K
Market Cap
$17.83M
Enterprise Value$16.33M
Total Cash (Recent Filing)$6.03M
Total Debt (Recent Filing)$4.53M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding17,307,402
10 Day Avg. Volume69,445
30 Day Avg. Volume66,914
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.09
Price to Sales (P/S)0.38
P/FCF Ratio-8.91
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue0.31
Enterprise Value/Gross Profit0.85
Enterprise Value/Ebitda-6.08
Forecast
1Y Price Target
$2.75Price Target Upside123.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$56.55M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueIridex's business mixes capital equipment placements with high-margin recurring consumables and service revenue tied to procedure volumes. An installed base that generates repeatable probe and accessory purchases provides durable, predictable aftermarket cash flow that supports margin stability and revenue visibility over multiple years.
Revenue Recovery And Product MomentumRevenue growth driven across Cyclo G6, medical retina and surgical retina indicates improving end-market demand and successful commercial execution. Consistent multi-product growth reduces reliance on a single product, supporting sustainable top-line expansion and better leverage of fixed costs over the medium term.
Sustained Cost-reduction ProgramMaterial expense reductions and planned HQ consolidation are structural actions that lower the firm's fixed cost base. These multi-quarter initiatives improve operating leverage, raise the breakeven revenue level, and increase the probability of converting revenue growth into consistent positive cash flow and EBITDA over 2026–2027.
Bears Say
Negative Cash Flow Still PresentAlthough cash burn has materially improved, the company has not yet demonstrated repeatable positive free cash flow at the annual level. Continued negative cash generation constrains reinvestment, increases reliance on external financing if setbacks occur, and reduces resilience to cyclical or regional demand shocks.
Gross Margin Compression And Manufacturing CostsSustained margin pressure from tariffs, elevated product costs, and lower capitalization of overhead directly erodes profitability and limits cash generation. The planned contract-manufacturing transition should help, but it is multi-year and carries execution and timing risk before full margin benefits accrue.
Thin Equity And Limited Balance-sheet CushionA slim equity base and modest cash reserves leave limited room to absorb operational setbacks or finance strategic investments without dilutive or costly capital. Even with manageable debt today, the balance sheet offers little cushion if revenue or margin recovery stalls, increasing refinancing and solvency risk over the medium term.
Iridex News
IRIX FAQ
What was Iridex Corp’s price range in the past 12 months?
Iridex Corp lowest stock price was $0.87 and its highest was $1.65 in the past 12 months.
What is Iridex Corp’s market cap?
Iridex Corp’s market cap is $17.83M.
When is Iridex Corp’s upcoming earnings report date?
Iridex Corp’s upcoming earnings report date is May 19, 2026 which is in 34 days.
How were Iridex Corp’s earnings last quarter?
Iridex Corp released its earnings results on Mar 26, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.01.
Is Iridex Corp overvalued?
According to Wall Street analysts Iridex Corp’s price is currently Undervalued.
Does Iridex Corp pay dividends?
Iridex Corp does not currently pay dividends.
What is Iridex Corp’s EPS estimate?
Iridex Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iridex Corp have?
Iridex Corp has 17,307,402 shares outstanding.
What happened to Iridex Corp’s price movement after its last earnings report?
Iridex Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went down -26.667%.
Which hedge fund is a major shareholder of Iridex Corp?
Currently, no hedge funds are holding shares in IRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iridex Corp
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
IRIX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress and financial improvement: revenue growth, significant operating expense reductions, the company’s first positive adjusted EBITDA in recent history, and positive operating cash flow in the quarter. These positives are tempered by margin pressure from higher manufacturing costs and tariffs, inventory write-downs, and notable regional headwinds (Middle East, China, Japan) that constrained sales and led management to provide conservative guidance excluding the Middle East. Management outlined credible cost-saving initiatives (G&A relocations, HQ move, contract manufacturing transition) expected to improve margins over 2026–2027, but those benefits are multi-quarter in delivery and carry execution risk. Overall, the call emphasizes a clear operational turnaround with some material but manageable near-term risks.View all IRIX earnings summariesIRIX Stock 12 Month Forecast
Average Price Target
$2.75
▲(123.58% Upside)
Technical Analysis
Sintx Technologies
―
PAVmed
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Envoy Medical
―
Ownership Overview
10.83% Insiders
3.65% Mutual Funds
8.23% Other Institutional Investors
74.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---